CorVel Valuation

Is CRVL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CRVL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CRVL ($344.74) is trading above our estimate of fair value ($150.54)

Significantly Below Fair Value: CRVL is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CRVL?

Key metric: As CRVL is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for CRVL. This is calculated by dividing CRVL's market cap by their current earnings.
What is CRVL's PE Ratio?
PE Ratio	72.4x
Earnings	US$81.52m
Market Cap	US$5.90b

CRVL key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	6.9x
Enterprise Value/EBITDA	44.8x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does CRVL's PE Ratio compare to its peers?

The above table shows the PE ratio for CRVL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	24.2x
OPCH Option Care Health	17.9x	4.4%	US$3.7b
CHE Chemed	27.6x	8.8%	US$8.3b
AMED Amedisys	35.6x	38.7%	US$2.9b
DVA DaVita	15.9x	4.3%	US$13.1b
CRVL CorVel	72.4x	n/a	US$5.9b

Price-To-Earnings vs Peers: CRVL is expensive based on its Price-To-Earnings Ratio (72.4x) compared to the peer average (24.2x).

Price to Earnings Ratio vs Industry

How does CRVL's PE Ratio compare vs other companies in the US Healthcare Industry?

3 Companies	Price / Earnings	Estimated Growth	Market Cap
NEUE NeueHealth	1.5x	n/a	US$41.24m
IDXG Interpace Biosciences	2.6x	n/a	US$12.54m
FZMD Fuse Medical	1.1x	n/a	US$4.22m

No more companies available in this PE range

3 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: CRVL is expensive based on its Price-To-Earnings Ratio (72.4x) compared to the US Healthcare industry average (25.1x).

Price to Earnings Ratio vs Fair Ratio

What is CRVL's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CRVL PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	72.4x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate CRVL's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Centene

US$29.0b

Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

CNC

US$57.46

-5.4%

-21.0%

Lantheus Holdings

US$5.3b

Develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.

LNTH

US$76.83

-8.6%

11.2%

Enhabit

US$369.6m

Provides home health and hospice services in the United States.

EHAB

US$7.35

-6.8%

-25.2%